← Back to Clinical Trials
Recruiting NCT04804930

NCT04804930 Trichoscopy and Systemic Scleroderma

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT04804930
Status Recruiting
Phase
Sponsor University Hospital, Lille
Condition Scleroderma, Systemic
Study Type OBSERVATIONAL
Enrollment 200 participants
Start Date 2021-11-08
Primary Completion 2026-05

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL
Interventions
picture

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 200 participants in total. It began in 2021-11-08 with a primary completion date of 2026-05.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

* Few data are available on scalp involvement in systemic scleroderma. * Few data are available on the association between scalp abnormalities and features of systemic scleroderma * Trichoscopy is a simple, reproducible, noninvasive examination that is part of the examination of hairy areas in routine dermatologic practice * There is a lack of simple, noninvasive examinations to evaluate patients with systemic scleroderma The objective will be to evaluate the contribution of trichoscopy in the evaluation of patients with systemic scleroderma

Eligibility Criteria

Inclusion Criteria: * Patient who fulfils the Systemic scleroderma ACR-EULAR 2013 criteria * Signed informed consent * Being social insured Exclusion Criteria: * Patients aged less than 18 years old * patients under legal protection * patients deprived of their liberty * patients in emergency situations * patients who refused or unable to give informed consent * For the control group: sclap inflammatory disease active the day of the examination

Contact & Investigator

Central Contact

Vincent Sobanski, MD

✉ vincent.sobanski@chru-lille.fr

📞 0320445962

Principal Investigator

Vincent Sobanski, MD

PRINCIPAL INVESTIGATOR

University Hospital, Lille

Frequently Asked Questions

Who can join the NCT04804930 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Scleroderma, Systemic. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT04804930 currently recruiting?

Yes, NCT04804930 is actively recruiting participants. Contact the research team at vincent.sobanski@chru-lille.fr for enrollment information.

Where is the NCT04804930 trial being conducted?

This trial is being conducted at Lille, France.

Who is sponsoring the NCT04804930 clinical trial?

NCT04804930 is sponsored by University Hospital, Lille. The principal investigator is Vincent Sobanski, MD at University Hospital, Lille. The trial plans to enroll 200 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology